Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|21|25|2892-2901

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.25, 2014-08, pp. : 2892-2901

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

By Rizzo Manfredi   Corrado Egle   Patti Angelo Maria   Rini Giovam Battista   Mikhailidis Dimitri P  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 647-655

Informa Healthcare

Access to resources Recommend Favorite

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk

By  

Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. : 894-902

Bentham Science Publishers

Access to resources Recommend Favorite

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

By  

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3858-3868

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment options for managing atherogenic dyslipidemia and fatty liver disease

By Rizzo Manfredi   Montalto Giuseppe   Al-Rasadi Khalid  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1065-1068

Informa Healthcare

Access to resources Recommend Favorite

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

By Rizzo Manfredi   Christ Emanuel R   Rini Giovam Battista   Spinas Giatgen A   Berneis Kaspar  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2295-2303

Informa Healthcare

Access to resources Recommend Favorite